HUMAN ANTIBODIES & HYBRIDOMAS
9-11 November 2016, Hilton Hotel, Belfast, Northern Ireland, UK

FINAL ORAL PROGRAMME

HAH 2016

SCIENTIFIC ADVISORY COMMITTEE

Programme Chairman: Professor Mark Glassy (IMSA, San Diego, USA)

Mirek Gorny (New York University School of Medicine, New York, USA)
Henry Lowman (Triphaseco, La Jolla, California, USA)
Chris Scott (The Queen’s University, Belfast, Northern Ireland, UK)
Roberto Burioni (Università Vita-Salute San Raffaele, Milan, Italy)
Jim Larrick (Panorama Research Inc., USA)
Alois Lang (GeNeuro SA, Geneva, Switzerland)
David P. Humphreys (UCB, Slough, UK)
Markus Enzelberger (MorphoSys AG, Martinsried, Germany)
Eszter Nagy (Arsanis GmbH, Vienna, Austria)
Sachdev Sidhu (University of Toronto, Canada)
Neil Brewis (F-star, Cambridge, UK)

Paul Kerr (Fusion Antibodies, Northern Ireland, UK)
Yan Wu (Kadmon Pharmaceuticals LLC, New York, USA)
Bob Kelley (Genentech Inc., South San Francisco, USA)
David Naor (The Hebrew University, Jerusalem, Israel)
Lynn MacDonald (Regeneron Pharmaceuticals, Tarrytown, New York, USA)
Jody Berry (Grifols, Emeryville, California, USA)
Maria Groves (Medimmune, Cambridge, UK)
Dale Ludwig (ImClone Inc., New York, USA)
Hermann Katinger and Dietmar Katinger
(Polymun Scientific Immunobiologische Forschung GmbH, Vienna, Austria)
Andrew Serafini (Kilpatrick Townsend, Seattle, Washington, USA)
Aaron Sato (SUTRO Biopharma, South San Francisco, California, USA)
**SESSION 1: OPENING PLENARY**

Moderator: Mark C. Glassy  
(Nascent Biologics Inc., San Diego, California, USA)

09.00-09.30
Donald Capra Lecture:
‘Human monoclonal antibodies: An ongoing fascinating story’
Professor Michael Steinitz  
(Hebrew University of Jerusalem, Jerusalem, Israel)

09.30-10.00
‘Applied Healthspan Engineering: A role for antibodies?’
James W. Larrick  
(Panorama Research Inc., Sunnyvale, California, USA)

10.00-10.30
‘Zmapp and beyond’
Ken Payle  
(MAPP Biopharmaceuticals Inc., San Diego, California, USA)

10.30-11.00
Coffee Break

**SESSION 2: PLENARY – TECHNOLOGY**

Moderator: James W. Larrick  
(Panorama Research Inc., Sunnyvale, California, USA)

11.00-11.30
‘Converting rabbit hybridoma into recombinant antibodies with effective transient production in an optimized human expression system’
Dr. Tim Welsink  
(InVivo BioTech Services GmbH, Hennigsdorf bei Berlin, Germany)

11.30-12.00
‘Disease biology driven antibody discovery’
Stephan Fischer  
(MAB Discovery GmbH, Neuried, Germany)

12.00-12.30
‘CelliGO™ – discovery of therapeutic antibodies for challenging targets using single-B-cell screening by nano-droplet microfluidics’
Adam Woolfe  
(HiFiBiO BV, Paris, France)

12.30-13.00
‘Integrating Insilico 3-D modelling for the optimization of monoclonal antibodies’
Anthony O’Kane  
(Fusion Antibodies, Belfast, Northern Ireland, UK)

13.00-14.00
Lunch Break

**SESSION 3: ANTIBODY DRUG CONJUGATES**

Moderator: Roger Beerli  
(NBE-Therapeutics AG, Basel, Switzerland)

14.00-14.25
‘Highly potent, anthracycline-based ADCs generated by enzymatic, site-specific conjugation’
Roger Beerli  
(NBE-Therapeutics AG, Basel, Switzerland)

14.25-14.50
‘Antibody drug nanoconjugates for the treatment of cancer’
Christopher Scott  
(Queen’s University of Belfast, Belfast, Northern Ireland, UK)

14.50-15.15
‘Development of the ADC’s for application in gynaecological cancers’
R. Steven Conlan 1, Asa Frostell 2, Tim Fagge 2, Belen Pan Castillo 1,  
Gareth D. Healey 3, Jetzabel Garcia Parra 1 and Deyarina Gonzalez 1  
(1 Swansea University Medical School, Swansea, Wales, UK; 2 GE Healthcare, UK/Sweden)

15.15-15.35
‘De novo antibody generation and selection for development of an ADC’
Jan Schouten  
(Synthion Biopharmaceuticals BV, Nijmegen, The Netherlands)

15.35-16.00
‘Mirvetuximab soravtansine: Advancing towards phase III’
John Lambert  
(Immunogen Inc., Waltham, Massachusetts, USA)

16.00-16.15
Tea Break

**SESSION 4: TECHNOLOGY**

Moderator: David P. Humphreys  
(UCB-New Medicines, Slough, Berkshire, UK)

16.15-16.35
‘Next generation VelocImmune® mice’
Lynn Macdonald  
(Regeneron Pharmaceuticals Inc. Tarrytown, New York, USA)

16.35-16.55
‘Delineation of the epitope: New applications of arrays’
Jaap Willem Back  
(Pepscan Therapeutics BV, Lelystad, The Netherlands)

16.55-17.15
‘Functional therapeutic antibody hits to challenging targets using the CelliGO™ platform’
Marcel Reichen  
(HiFiBiO BV, Paris, France)

17.15-17.30
‘Radium-223 in Metastatic Prostate Cancer: The beginning of a new era for targeted radionuclide therapy?’
Joe O’Sullivan  
(The Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland, UK)

17.30
Bus transport to HAH 2016 Welcome Reception at the Long Gallery in the Parliament Buildings, Stormont Castle

19.30
Bus transport back to Hilton Hotel (arriving 20.00 approx)
### SESSION 5: OTHER INDICATIONS

**Moderator:** Lynn Macdonald  
(Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09.00-09.30| ‘Novel oxyntomodulin co-agonist for treatment of diabesity’  
James W. Larrick  
(Panorama Research Inc., Sunnyvale, California, USA) |
| 09.30-10.00| ‘New discovery engine to generate the functional therapeutic mAbs targeting at GPCRs for fibrosis, cancer and metabolic diseases’  
Kiyoshi Takayama  
(NB Health Laboratory Co., Ltd., Kawaguchi City, Saitama, Japan) |
| 10.00-10.30| ‘Targeting ADAM17, a novel therapeutic antibody’  
Peter Lowe  
(Institute de Recherche Pierre Fabre, St Julien en Genevois, France) |
| 10.30-11.00| ‘From DART to Trident: Applications of bi- and tri-specific binding proteins in autoimmunity, oncology and infectious disease’  
Syd Johnson  
(Macrogenics Inc., Rockville, Maryland, USA) |
| Coffee Break |                                                                                             |

### SESSION 6: MOLECULAR BIOLOGY

**Moderator:** Yan Wu  
(Kadmon Inc., New York, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11.30-12.00| ‘Statistical design for effector function engineering of hexameric Fc domains’  
David P. Humphreys  
(UCB-New Medicines, Slough, Berkshire, UK) |
| 12.00-12.20| ‘Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody. The rationale and the journey to development this into a therapeutic candidate?’  
Nick Geukens  
(PharmAbs, K.U.Leuven, Leuven, Belgium) |
| 12.20-12.40| ‘Approaches to target the inside of the cell’  
Andrea Marschall and Stefan Duebel  
(Technische Universität Braunschweig, Braunschweig, Germany) |
| 12.40-13.00| ‘Microdroplet-based massive kinetic analyses reveal secretion rate and affinity from individual antibody secreting cells’  
Pierre Bruhns  
(Institut Pasteur, Paris, France) |
| 13.00-14.00| Lunch Break                                                                                 |

### SESSION 7: CNS/AUTOIMMUNE & INFECTIOUS DISEASES

**Moderator:** Syd Johnson  
(Macrogenics Inc., Rockville, Maryland, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 14.00-14.30| ‘Antibody therapeutics for CNS diseases and delivery across the BBB’  
George Thorn  
(ADPE, MedImmune, Cambridge, UK) |
| 14.30-15.00| ‘Proof of concept studies for monoclonal antibodies against respiratory viruses’  
Rob Lambkin-Williams  
(hVIVO Ltd, London, UK) |
| 15.00-15.20| ‘In vivo Herpes simplex virus (HSV) pre- and post-infection neutralizing activity of a single anti-HSV/gD human monoclonal antibody’  
N. Mancini, N. Clementi, M. Clementi and R. Burioni  
(University “Vita-Salute” San Raffaele, Milan, Italy) |
| 15.20-15.40| ‘Anti-inflammatory therapeutic effects of human 5-mer RA-peptide, targeting autoimmune inflammations’  
David Naor, Dr Shmuel Cohen, Dr Keren-Or Amar, Dr Lora Eshkar-Sebban and Michal Melamed  
(The Lautenberg Center of Immunology and Cancer Research, Hebrew University of Jerusalem, Jerusalem, Israel) |
| 15.40-16.00| Tea Break                                                                                  |

### SESSION 8: PLENARY SESSION

**Moderator:** Mark C. Glassy  
(Nascent Biologics Inc., San Diego, California, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16.00-16.30| ‘New approaches to antibody engineering in plant based systems?’  
Julian Ma  
(St George’s University of London, London, UK) |
| 16.30-17.00| ‘Efficient mining of the B cell repertoire: Finding rare antibodies with desirable characteristics’  
Victoria O’Dowd  
(UCB-Celltech, Slough, Berkshire, UK) |
| 17.00-17.30| ‘Microarray patches for delivery of therapeutic antibodies’  
Aaron Courtenay and Ryan Donnelly  
(Queen’s University of Belfast, Belfast, Northern Ireland, UK) |
| 18.30 onwards| Fusion Antibodies sponsored canapés and entertainment in a reserved area at The Dark Horse Bar, Hill St, Belfast BT1 2LB (central Cathedral quarter) |
SESSION 9: CANCER

Moderator: David Naor
(The Lautenberg Center of Immunology and Cancer Research, Hebrew University of Jerusalem, Jerusalem, Israel)

09.00-09.30
‘Moving pritumumab into the oncology clinic’
Santosh Kesari
(UCSD Moores Cancer Center, San Diego, California, USA)

09.30-10.00
‘Anti-PD-L1/IL-15 targeted immunotherapy promotes enduring antitumor immunity’
Yan Wu
(Kadmon Inc., New York, USA)

10.00-10.30
‘A new monoclonal antibody detects down-regulation of Protein Tyrosine Phosphatase Receptor Type γ (PTPRG) in chronic myeloid leukemia patients’
Marzia Vezzalini1, Andrea Mafficini1,2, Luisa Tomasello3, Erika Lorenzetto3, Elisabetta Moratti1, Zeno Fiorini1, Tessa Laurie Holyoake4, Francesca Pellicano4, Mauro Krampera5, Cristina Tecchio5, Mohamed Yassin6, Nader Al-Dewik7, Mohammed Arab8, Ali Al Sayab6, Maria Monne8 and Claudio Sorio1
(1 University of Verona, Verona, Italy; 2 University and Hospital Trust of Verona, Verona, Italy; 3 Dept. of Neurological, Neuropsychological, Morphological and Motor Sciences, Section of Physiology, University of Verona, Verona, Italy; 4 Paul O’Gorman Leukemia Research Centre, University of Glasgow, Glasgow, UK; 5 Department of Medicine, University of Verona, Verona, Italy; 6 National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar; 7 Qatar Medical Genetics Center, Hamad Medical Corporation (HMC), Doha, Qatar; 8 San Francesco Hospital, Nuoro, Italy)

10.30-11.00
‘Costimulatory T-cell engagement by the CD137/HER2 bispecific, PRS-343, leads to tumor-targeted immune modulation’
Thomas Jaquin
(Pieris Pharmaceuticals, Freising, Munich, Germany)

11.00-11.30
Coffee Break

SESSION 10:

Moderator: Mark C. Glassy
(Nascent Biologics Inc., San Diego, California, USA)

11.30-12.00
‘Benefits of bispecific mAb antibodies targeting EGFR and HGF’
Mihriban Tuna
(f-Star, Cambridge, UK)

12.00-12.30
‘What is the best indication for your drug? How HuMax-IL8 became an immune-oncology asset’
Maarten Dechateau
(Buzzard Pharmaceuticals, Stockholm, Sweden)

12.30-13.30
Lunch Break

13.30-14.00
‘Construction and usage of large antibody libraries in mammalian cells’
Neil Butt
(IONTAS, Babraham, Cambridge, UK)

14.00-14.30
‘Selective targeting of adrenomedullin signalling for treatment of cancer’
G.O. Richards and T.M. Skerry
(University of Sheffield, Sheffield, UK)

14.30-15.00
‘T cell recruitment in oncology: Many tools are required’
Jim Johnston
(Amgen Inc., Thousand Oaks, California, USA)

15.00-15.10
Closing Remarks
Professor Mark C. Glassy
(Nascent Biologics Inc., San Diego, California, USA)

15.10
Tea & Departure

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.